NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY;Celgene Corporation
发明人:
IHA, Hidekatsu,IKEBE, Emi
申请号：
EP16804297
公开号：
EP3304076A4
申请日:
2016.06.01
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering a treatment compound to a subject having cancer； obtaining a sample from the subject； determining the ratio of a first biomarker level to a second biomarker level in the sample from the subject, wherein at least one of the biomarkers is a CRBN-associated protein； and diagnosing the subject as being likely to be responsive to the treatment compound if the ratio of the biomarker levels in the sample of the subject changes as compared to a reference ratio of the biomarker levels.
